- Home
- PRAX vs IIIV Comparison
PRAX vs IIIV Comparison
Compare PRAX & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- IIIV
- Stock Information
- Founded
- PRAX 2015
- IIIV 2012
- Country
- PRAX United States
- IIIV United States
- Employees
- PRAX N/A
- IIIV N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- PRAX Health Care
- IIIV Technology
- Exchange
- PRAX Nasdaq
- IIIV Nasdaq
- Market Cap
- PRAX 599.7M
- IIIV 612.5M
- IPO Year
- PRAX 2020
- IIIV 2018
- Fundamental
- Price
- PRAX $38.55
- IIIV $24.71
- Analyst Decision
- PRAX Strong Buy
- IIIV Buy
- Analyst Count
- PRAX 10
- IIIV 7
- Target Price
- PRAX $116.50
- IIIV $29.57
- AVG Volume (30 Days)
- PRAX 320.6K
- IIIV 420.4K
- Earning Date
- PRAX 05-02-2025
- IIIV 05-08-2025
- Dividend Yield
- PRAX N/A
- IIIV N/A
- EPS Growth
- PRAX N/A
- IIIV 4907.14
- EPS
- PRAX N/A
- IIIV 4.75
- Revenue
- PRAX $8,122,000.00
- IIIV $241,651,000.00
- Revenue This Year
- PRAX N/A
- IIIV $5.32
- Revenue Next Year
- PRAX N/A
- IIIV $3.94
- P/E Ratio
- PRAX N/A
- IIIV $7.31
- Revenue Growth
- PRAX 270.02
- IIIV 5.59
- 52 Week Low
- PRAX $26.70
- IIIV $18.77
- 52 Week High
- PRAX $91.83
- IIIV $29.80
- Technical
- Relative Strength Index (RSI)
- PRAX 53.72
- IIIV 44.54
- Support Level
- PRAX $35.21
- IIIV $24.88
- Resistance Level
- PRAX $38.90
- IIIV $25.72
- Average True Range (ATR)
- PRAX 2.09
- IIIV 1.04
- MACD
- PRAX 0.07
- IIIV -0.13
- Stochastic Oscillator
- PRAX 69.58
- IIIV 15.47
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.